Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
As more states expand adult Medicaid dental benefits, participation remains low and GOP-backed federal cuts threaten to reverse recent progress, raising concerns for physicians and dentists.